不同部位高龄结直肠癌伴肠梗阻患者的治疗及预后

目的比较不同部位结直肠癌伴肠梗阻的高龄患者的治疗和预后。方法收集157例结直肠癌伴肠梗阻的高龄患者,对治疗效果与预后结果进行评价。按梗阻部位不同分为A组(近段梗阻)61例,B组(远段梗阻)96例。结果两组术后并发症和死亡率差异无统计学意义(P>0.05)。糖尿病、高血压、低蛋白血症、术中出血量≥500 ml,结肠穿孔腹膜炎是影响结直肠癌患者伴肠梗阻的高龄患者预后的独立因素。结论采取积极措施,早诊断早治疗,积极纠正术前并发症可提高结直肠癌伴肠梗阻的高龄患者治疗效果,减少术后并发症,改善预后,具有重要的临床意义。     

超细内镜辅助金属支架置入治疗结直肠癌合并急性肠梗阻的临床研究（含视频）

目的 探讨超细内镜辅助置入肠道金属支架治疗结直肠癌合并急性肠梗阻的临床疗效。方法 对56例结直肠癌合并急性肠梗阻患者行超细内镜辅助下置入国产肠道金属支架治疗，观察治疗效果。结果 56例患者中直肠癌11例，乙状结肠癌18例 ，降结肠癌13例，横结肠癌9例，升结肠和（或）回盲部癌5例。肠道支架成功置入52例（92.9%），支架置入手术时间30~90 min，无穿孔、出血、感染及心肺功能意外等并发症。24~48 h内急性肠梗阻缓解52例，支架置入成功后缓解率100.0%。支架置入失败4例（7.1%），均急诊外科手术造瘘治疗。46例患者支架置入后7~10 d行肠癌根治术，术后无一例并发吻合口瘘，无一例术后30 d死亡，3年生存率为58.7%（27/46）。结论 超细内镜辅助肠道金属支架置入治疗结直肠癌合并急性肠梗阻安全、有效，能够及时缓解或消除患者肠梗阻症状，外科根治术后并发症发生率低。     

内镜下穿孔修补术治疗肝硬化合并消化道穿孔患者疗效观察

目的探讨内镜下穿孔修补术治疗肝硬化合并消化道穿孔患者的疗效。方法将78例肝硬化合并消化道穿孔患者随机分为治疗组39例和对照组39例。给予治疗组内镜下穿孔修补术治疗,给予对照组传统的手术切除治疗。结果所有患者都顺利完成手术;治疗组手术时间、术中出血量、术后下床活动时间和术后住院时间分别为(128.34±15.33)min、(287.38±100.87)ml、(2.00±2.75)d和(6.25±2.95)d,均显著短于或少于对照组[分别为(123.87±15.77)min、(444.39±124.88)ml、(4.50±3.00)d和(9.85±4.66)d,P0.05];治疗组术后肺部感染、切口感染、肠梗塞、腹腔感染等并发率显著低于对照组(P0.05);治疗组生存时间为(47.44±6.44)个月,1 a生存率为97.4%,而对照组分别为(34.98±5.29)个月和82.1%(P0.05)。结论内镜下穿孔修补术用于肝硬化合并消化道穿孔患者具有微创,术后并发症少等特点,从而可改善远期生存情况。     

老年结直肠癌腹腔镜手术患者术后肠梗阻发生率及影响因素

目的探讨老年结直肠癌腹腔镜手术患者术后肠梗阻的发生率及影响因素。方法选择2013年1月至2017年2月在该院进行腹腔镜手术治疗的老年结直肠癌患者288例为研究对象,术后至少随访30 d,记录术后肠梗阻的发生率;根据术后是否发生肠梗阻分为肠梗阻组和非肠梗阻组,采用单因素和多因素logistic回归分析法分析其影响因素。结果 288例老年结直肠癌腹腔镜手术患者,术后30 d内肠梗阻的发生率为6.25%(18/288);单因素分析显示:性别、年龄、术前肠梗阻、肿瘤位置、TNM分期、吸烟史、腹部手术史、手术时间、肿瘤分化程度等是老年结直肠癌腹腔镜手术术后肠梗阻发生的影响因素(P0.05);多因素分析显示:男性、年龄≥70岁、术前有肠梗阻、直肠癌、TNM分期为Ⅲ～Ⅳ期及手术时间≥2 h是老年结直肠癌腹腔镜手术术后肠梗阻发生的危险因素(P0.05)。结论老年结直肠癌腹腔镜手术患者术后肠梗阻的危险因素较多,医护人员应采取相应的预防措施,尽可能降低术后肠梗阻的发生率,提高治疗水平。     

急性结直肠癌性梗阻内镜治疗的临床价值

目的探讨经内镜放置金属支架和肠梗阻导管治疗急性结直肠癌性梗阻的可行性与临床疗效。方法在X线辅助下,经内镜放置金属支架或肠梗阻导管治疗26例急性结直肠癌性梗阻的患者。其梗阻的部位分别为直肠14例,乙状结肠8例,降结肠3例,横结肠1例。结果 26例结直肠癌性梗阻中,20例放置金属支架,成功18例；6例放置肠梗阻导管,成功6例,总的操作成功率为92．3％(24／26)。操作成功的24例中。1例无效,23例术后1～2 d梗阻症状缓解或消除,临床有效率为88．5％(23／26)。其中13例为永久性姑息治疗,10例经内镜治疗解除梗阻后7～10d行1期肿瘤切除,术后均恢复顺利,无感染及吻合口漏等并发症发生。1例直肠癌术后复发伴盆腔广泛转移者治疗失败,1例乙状结肠癌广泛转移者术中穿孔而急诊行Hartmann术。1例术后6周支架移位,导致梗阻复发。置入第2根支架后缓解。1例术后1个月粪块堵塞支架。以探条及网篮疏通后缓解。结论经内镜放置金属支架或肠梗阻导管治疗急性结直肠癌性梗阻。能够有效缓解患者的梗阻症状,避免行结肠造瘘术,显著降低患者的创伤和痛苦。提高患者的生活质量。     

手术治疗结直肠癌合并急性肠梗阻156例临床分析

目的探讨结直肠癌合并急性肠梗阻患者的手术治疗方法。方法回顾性分析156例行手术治疗的结直肠癌合并急性肠梗阻患者的临床资料。结果本组131例行结肠一期切除吻合术,其中21例行左半结肠切除,行横结肠切除8例,行右半结肠切除术61例,行乙状结肠切除26例,Dixon术15例;行分期手术13例;3例行一期造瘘、二期肿瘤切除肠吻合术;因肿瘤无法切除而行单纯造瘘术9例。本组围手术期死亡3例。153例肠梗阻得到缓解。术后发生切口感染9例,吻合口漏8例,肺部感染2例,输尿管损伤1例,经对症处理后痊愈。随访9个月～5年。术后1年生存率为90.1%(136/151),3年生存率为51.7%(78/151),5年生存率为40.4%(61/151)。结论结直肠癌合并急性肠梗阻确诊后应及早手术治疗。应根据患者的具体情况选择术式,在严格掌握适应证的情况下,尽量争取行一期肠切除吻合术。     

烟雾病合并肾动脉狭窄的临床特征及治疗预后

目的探讨烟雾病合并肾动脉狭窄(RAS)的临床特征及治疗预后。方法回顾性分析解放军第三○七医院神经外科2009年3月至2012年6月收治的15例烟雾病合并RAS患者及基线情况匹配的30例无RAS烟雾病患者的首发症状、颅内血管病变情况、肾动脉病变情况、治疗及随访结果等临床资料。结果 (1)烟雾病合并RAS患者占同期收治的烟雾病患者总数的1.6%(15/927)。RAS组左侧RAS有5例,右侧RAS有4例,双侧RAS有6例;轻度狭窄占71.4%(15/21侧),近端狭窄占85.7%(18/21侧);RAS组高血压患者(80.0%,12例)显著高于无RAS烟雾病组(30.0%,9例),差异有统计学意义(χ2=10.045,P0.05)。两组患者铃木分期分布差异有统计学意义(Z=-6.184,P0.01)。(2)对RAS行介入治疗的4例,术后血压均下降至正常。介入治疗后造影随访3例,随访时间9~108个月,肾动脉均无再狭窄发生。结论烟雾病RAS患者的高血压患病率较未合并RAS显著升高,并且颅内血管病变程度与未合并RAS患者存在差异。RAS以近端、轻度狭窄为主,血管介入治疗烟雾病合并严重RAS有效,但长期预后需进一步随访。     

结直肠癌患者术后肠梗阻发生风险列线图预测模型的构建及评估

目的分析结直肠癌患者术后肠梗阻发生的危险因素,构建列线图预测模型并进行评估。方法回顾性分析2018年6月至2020年8月淄博市中心医院西院收治的经手术病理确诊的283例结直肠癌患者,所有患者均行结直肠癌根治术。其中31例患者术后1个月发生肠梗阻。比较肠梗阻与非肠梗阻患者一般临床资料差异。采用多因素logistics回归分析筛选结直肠癌患者术后肠梗阻发生的危险因素,并基于筛选出的危险因素建立术后肠梗阻发生风险的列线图预测模型,使用受试者操作特征(ROC)曲线评估模型的区分度并进行一致性检验。结果 283例结直肠癌患者术后肠梗阻发生率为11.0%(31/283),其中机械性肠梗阻15例,麻痹性肠梗阻9例,炎症性肠梗阻7例。Logistic回归分析结果显示,肿瘤TNMⅢ期、中转开腹、右半结肠切除术、手术时间、既往大肠肿瘤切除史是结直肠癌患者术后肠梗阻发生的独立危险因素(P0.05);将独立危险因素引入R软件(R3.6.3)构建列线图模型,曲线下面积为0.919 (95%CI 0.862-0.975),列线图校准曲线斜率接近1。Hosmer Lemeshow拟合优度检验=8.576,P=0.379。结论基于结直肠癌患者术后肠梗阻发生的危险因素如肿瘤TNM分期、手术类型、手术方式、手术时间、既往大肠肿瘤切除史建立的列线图预测模型具有良好的区分度与一致性,可为结直肠癌术后肠梗阻的预防提供一定指导。     

老年癌性结直肠梗阻患者行肠造瘘的临床价值

目的探讨老年晚期结直肠癌合并癌性梗阻患者行肠造瘘的临床价值。方法回顾性分析我院2006年6月至2011年6月5年间收治的82例老年癌性结肠梗阻患者的临床资料。结果造瘘组在营养状况、(再)手术率、生存时间、生活质量、满意度调查等方面均优于单纯最佳支持治疗组,2组比较差异有统计学意义(P<0.05)。结论为老年癌性结肠梗阻而无法耐受肿瘤切除手术的患者施行肠造瘘术,是一种简便、安全、有效的治疗手段。     

内镜下肠道支架置入术在治疗结直肠癌并肠梗阻中的应用和价值

目的:评价肠道支架在治疗结直肠癌并急性肠梗阻中的安全性、有效性及临床应用价值.方法:收集南昌大学第一附属医院2010-01/2014-12因结直肠癌性梗阻就诊患者,共263例,在内镜下和/或X射线监测下引导行支架置入治疗,分析放置支架成功率,术后并发症发生率,症状缓解率,手术切除率等指标.结果:258例放置支架成功(98.1%);术后发并穿孔1.1%(3例),出血3.8%(10例)、发热4.6%(12例),其他如支架脱落及移位等3.0%(8例);症状缓解率:腹痛97.3%(256例),腹胀98.1%(258例),肛门排便98.1%(258例);手术切除率:60例为姑息性治疗,198例行于支架置入术后5-13 d后行肠道准备后手术治疗,143例行一期手术切除肿瘤.结论:内镜下肠道支架置入能很好地解除肠梗阻症状,其中急诊内镜下支架置入可作为术前过渡治疗,可以将急诊手术转为择期手术,二期手术转为一期手术,减轻临床医生的手术难度和风险、降低术后等并发症发生率,减轻患者痛苦,提高了患者生存质量,值得大力推广应用.     

Comparison of surgical outcomes in patients with colorectal liver metastases versus non‐colorectal liver metastases: A Chinese experience

Aim: To compare the surgical treatment outcomes between patients with colorectal liver metastases (CLM) and non‐colorectal liver metastases (NCLM). Methods: The study population consisted of 132 patients undergoing hepatectomy at Tianjin Medical University Cancer Hospital between January 1996 and December 2008. Survival analyses were used to assess the differences in prognosis and survival between groups. Results: The primary tumor site was colorectal in 60 (45.5%), breast in 16 (12.1%), lung in 14 (10.6%), non‐colorectal gastrointestinal in 12 (9.1%), genitourinary in 10 (7.6%), pancreatobiliary tumor (n = 8, 6.1%) and others in 12 (9.1%). A curative liver resection was performed in all patients by pathological findings. After a median follow‐up of 32 months, the overall 3‐ and 5‐year survival rate was 44.7 and 29.5% in all patients, respectively. The 3‐ and 5‐year survival rates were 53.3 and 36.7% for liver metastases from colorectal tumors, 62.5 and 43.8% from breast, 60.0 and 40.0% from genitourinary neoplasm, 41.7 and 25.0% from non‐colorectal gastrointestinal cancer, 28.5 and 15.0% from lung, 12.5 and 0% from pancreatobiliary malignancies, and 41.7 and 8.3% from other sites, respectively. Conclusions: Hepatic resection is an effective and safe treatment for liver metastases mainly depending on primary tumor sites. Hepatic metastases from non‐colorectal gastrointestinal cancer, pulmonary and pancreatobiliary malignancies have the worst prognosis; those from breast and genitourinary neoplasm show the best prognosis.     

The survival rate and prognostic factors in 26 perforated colorectal cancer patients

Purpose The treatment for perforated colorectal cancer is not easy and the prognosis for this disease is not so predictable. There are some controversies about performing radical operations because colorectal cancer perforation was considered as an advanced stage disease due to the possibility of tumor cell dissemination through the perforation site. Methods We selected and enrolled 26 patients with perforated colorectal cancers among the 1,227 patients who underwent operation for colorectal cancer. These cases were retrospectively analyzed by using their medical records and clinicopathological data. Results Twenty-eight cases (2.3%) with perforated colorectal cancers were studied and the overall operative mortality rate was 11%. The overall 5-year survival rate was 57.8% when excluding the operative mortality. The overall 5-year cancer-free survival rate was 52.8%. There were significant differences in the survival rate and the cancer-free survival rate between the stages (p=0.008 and p<0.001, respectively). A univariate analysis of the prognostic factors revealed that the number of the metastatic lymph nodes (p=0.018) and the perforation proximal to the cancer (p=0.005) were significantly correlated to worse survival, and the higher number of the metastatic lymph nodes was correlated to a poorer cancer-free survival rate (p<0.001). Conclusion For the perforated colorectal cancers, the stage, the perforation proximal to the cancer, and the number of the metastatic lymph nodes were correlated, with the survival and the cancer-free survival as factors of a poor prognosis. The surgical approach selected for perforated colorectal cancer should be in line with the principles of an appropriate cancer operation because the clinical pathway of perforated colorectal cancer is similar to that of uncomplicated colorectal cancer.     

奥沙利铂联合氟尿嘧啶和亚叶酸钙方案治疗70岁及以上转移性结直肠癌的疗效和安全性

目的 对比观察奥沙利铂联合氟尿嘧啶和亚叶酸钙方案(FOLFOX4)治疗70岁及以上转移性结直肠癌患者与70岁以下患者的不良反应和疗效.方法 61例转移性结直肠癌患者,其中≥70岁组28例,＜70岁组33例,两组患者均接受FOLFOX4方案化疗,14 d为1个周期,治疗期间观察不良反应,3个周期后评价疗效.结果 61例患者均可评价不良反应及疗效.主要不良反应为骨髓抑制、胃肠道反应及神经毒性,≥70岁组腹泻的发生率高于＜70岁组,但主要为1～2度不良反应.≥70岁组白细胞和中性粒细胞下降的发生率高于＜70岁组(92.8%比78.8%和39.3%比36.3%),但差异无统计学意义.≥70岁组神经系统毒性发生率为46.5%,＜70岁组为36.4%,均为1～2度,两组间差异无统计学意义.≥70岁组患者近期有效率为25%,疾病控制率为71.4%,中位疾病进展时间(TTP)为6个月,＜70岁组患者近期有效率24.2%,疾病控制率84.8%,中位TTP 7个月,两组有效率和疾病控制率差异无统计学意义,而＜70岁组患者的中位TTP比≥70岁组略长.结论FOLFOX4方案同样适用于≥70岁转移性结直肠癌患者,其耐受性较好且疗效肯定.

Abstract：

Objective To observe the safety and efficacy of FOLFOX4 regiment in elderly versus young patients with advanced colorectal cancer. Methods There were 61 patients enrolled in this study, with 28 elderly patients aged 70 years and over, 33 young patients aged less than 70 years.They suffered from advanced/recurrent colorectal cancer and received FOLFOX4 regiment (Oxaliplatin +CF+5-FU). Every 14 days were as a cycle, and the therapeutic safety and efficacy were evaluated after three cycles. Adverse events and response to treatment were compared between the elderly and young patients. Results The main adverse effects were myelosuppression, gastrointestinal disturbance and neurotoxicity. The incidence rate of diarrhea was significantly higher in elderly patients than in young patients, but the most of diarrhea were at grade Ⅰ - Ⅱ. The incidence rates of leucocyte decrease and neutrophil decrease were higher in elderly patients than in young patients (92. 8% vs. 78. 8%, 39.3% vs. 36.3%), but there were no statistically significant differences between them. The incidence rate of neurotoxicity was 46.5% in elderly patients and 36.4% in young patients (P＞0. 05). The recent efficacy rate was 25%, disease control rate was 71.4% and median time-to-progression (TTP) was 6 months in elderly patients and 24.2%, 84.8% and 7 months in young patients (all P＞0.05). Conclusions FOLFOX4 regiment is well-tolerated and effective in both young and elderly patients.     

Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population

Purpose  

Mutations in KRAS and BRAF genes were associated with treatment failure from EGF receptor inhibitors in colorectal cancer (CRC) patients. However, whether these mutations were associated with survival in patients not treated with EGF receptor inhibitors remained controversial. Moreover, few data were available in Chinese. Therefore, we aimed to evaluate the impact of KRAS and BRAF mutations on the survival of Chinese CRC patients.     

Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases

BACKGROUND: The role of palliative resection of the primary tumour in patients who present with metastatic colorectal cancer is unclear. AIMS: This study compared the incidence of major intestinal complications in such patients who received chemotherapy treatment with or without prior palliative resection of the primary tumour. PATIENTS: The incidence of intestinal obstruction, perforation, fistula formation, and gastrointestinal haemorrhage, and the requirement for abdominal radiotherapy in patients with metastatic colorectal cancer treated at a single institution over a 10 year period was determined. RESULTS: Eighty two patients received initial treatment with chemotherapy without resection of the primary tumour (unresected group) and 280 patients had undergone prior resection (resected group). In the unresected group, the incidence of peritonitis, fistula formation, and intestinal haemorrhage was 2.4% (95% confidence interval (CI) 0.3-8.5%), 3.7% (95% CI 0.8-10.3%), and 3.7% (95% CI 0.8-10.3%), respectively, and was not significantly different from the resected group. Intestinal obstruction affected 13.4% (95% CI 6.9-22.7%) of patients in the unresected group and 13.2% (95% CI 9.2-17.2%) of patients in the resected group. More patients in the unresected group required >/=3 blood transfusions (14.6% v 7.5%; p=0.048) and abdominal radiotherapy (18.3% v 9.6%; p=0.03) than the resected group. CONCLUSIONS: The incidence of major intestinal complications in patients with unresected colorectal cancer and synchronous metastases who receive initial treatment with chemotherapy is low. Chemotherapy may be successfully used as initial treatment for such patients with no increased risk of most major intestinal complications compared with patients who have undergone initial resection of the primary tumour.     

内镜下射频热疗联合局部化疗治疗晚期大肠癌的随机对照研究

目的：探讨射频加局部化疗治疗晚期大肠癌的疗效,并与单纯射频治疗比较。方法选择晚期大肠癌失去手术切除时机患者55例行射频加局部化疗或单纯射频治疗,随机分为射频加局部化疗组（A组）27例、射频组（B组）28例,观察两组患者5年内肠梗阻缓解率、再转移率、生存率。结果 A组与B两组1～5年肠梗阻缓解率分别为88.9%vs 70.8%、95.8 vs 70%、89.5%vs 52.9%、100%vs 33.3%、100%vs 0,具有统计学差异（P＜0.05）;5年内再转移情况,A组27例无一例出现再转移,再转移率为0（0/27）,B组11例出现了新的转移病灶,再转移率为39.3%（11/28）,有统计学差异（P＜0.05）;A组5年生存率为44.4%（19/27）,B组为无一例生存,有统计学差异（P＜0.05）。结论内镜下射频热疗联合局部化疗能显著提高晚期大肠癌患者5年内肠梗阻缓解率和5年生存率,显著降低再转移率。     

Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients

AIM： To investigate the efficacy and safety of cape- citabine plus irinotecan ＋ bevacizumab in advanced or metastatic colorectal cancer patients. METHODS： Forty six patients with previously untreated, locally-advanced or metastatic colorectal cancer （mCRC） were recruited between 2001-2006 in a pro- spective open-label phase Ⅱ trial, in German commu- nity-based outpatient clinics. Patients received a stan- dard capecitabine plus irinotecan （CAPIRI） or CAPIRI plus bevacizumab （CAPIRI-BEV） regimen every 3 wk. Dose reductions were mandatory from the first cycle in cases of 〉 grade 2 toxicity. The treatment choice of bevacizumab was at the discretion of the physician. The primary endpoints were response and toxicity and sec- ondary endpoints included progression-free survival and overall survival. RESULTS： In the CAPIRI group vs the CAPRI-Bev group there were more female than male patients （47% vs 24%）, and more patients had colon as the primary tumor site （58.8% vs 48.2%） with fewer patients having sigmoid colon as primary tumor site （5.9% vs 20.7%）. Grade 3/4 toxicity was higher with CAPIRI than CAPIRI-Bev： 82% vs 58.6%. Partial response rates were 29.4% and 34.5%, and tumor control rates were 70.6% and 75.9%, respectively. No complete re- sponses were observed. The median progression-free survival was 11.4 mo and 12.8 mo for CAPIRI and CA- PIRI-Bev, respectively. The median overall survival for CAPIRI was 15 mo （458 d） and for CAPIRI-Bev 24 mo （733 d）. These differences were not statistically different. In the CAPIRI-Bev, group, two patients under- went a full secondary tumor resection after treatment, whereas in the CAPIRI group no cases underwent this procedure. CONCLUSION： Both regimens were well tolerated and offered effective tumor growth control in this out- patient setting. Severe gastrointestinal toxicities and thromboembolic events were rare and if observed were never fatal.     

Treatment outcomes of 70 cases of early esophageal carcinoma: 12 years of experience

Early esophageal cancer (EEC) has an excellent prognosis compared to advanced esophageal cancer. Nowadays, endoscopic mucosal resection (EMR) may offer another alternative to cure early cancers of the gastrointestinal tract. We aimed to evaluate the clinical outcomes of EEC in Korea after curative treatments; EMR or surgery. We retrospectively reviewed the medical records of patients diagnosed as EEC from January 1994 to August 2005 at Yonsei University Medical Center, Seoul, Korea. Among 888 patients diagnosed with esophageal cancer, 70 (7.9%) were included as EEC. Among them, 10 patients (14.3%) were treated by EMR, and 50 (71.4%) by operation. The treatment outcomes of EEC in relation to various clinicopathologic factors along with survival rates were analyzed. There were 18 cases (30%) of mucosal lesions and 42 cases (70%) of submucosal lesions. Overall 5-year survival rate was 84.3%. When comparing treatment outcomes between EMR-treated and operated groups, there were no significant differences in complete remission (80%vs. 84%), recurrence (20%vs. 16%) and 5-year survival rate (100%vs. 78.3%). EEC is a potentially curable entity with a good clinical prognosis. EMR can be considered as another treatment arm for EEC, along with surgical resection.     

Value of bevacizumab in treatment of colorectal cancer: A meta-analysis

AIM:To assess the efficacy and safety of bevacizumab in the treatment of colorectal cancer.METHODS:All randomized controlled trials of bevacizumab for the treatment of colorectal cancer from January 2003 to June 2013 were collected by searching the Cochrane Library, Pub Med, Chinese National Knowledge Infrastructure and Wanfang databases.The primary endpoint was overall survival(OS), and the secondary endpoints were progression-free survival, overall response rate and adverse events.Two reviewers extracted data independently.Statistical analyses were performed with Stata 12.0.The degree of bias was assessed using funnel plots for the effect size of OS at the primary endpoint.RESULTS:Following the inclusion criteria and exclusion criteria, ten studies comprising 6977 cases were finally included, of which nine were considered to be of high quality(4-7 points) and one of low quality(1-3 points).Our meta-analysis revealed the efficacy of bevacizumab in patients with colorectal cancer in terms of OS(HR = 0.848, 95%CI:0.747-0.963), progressionfree survival(HR = 0.617, 95%CI:0.530-0.719), and overall response rate(OR = 1.627, 95%CI:1.199-2.207).Regarding safety, higher rates of grade ≥ 3 hypertension, proteinuria, bleeding, thrombosis, and gastrointestinal perforation were observed in the bevacizumab treatment group(P 0.05); however, the incidence of serious toxicity was very low.There was no publication bias in the 10 reports included in this meta-analysis.CONCLUSION:The clinical application of bevacizumab in colorectal cancer is effective with good safety.